Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Jhaveri, K., Eli, L.D., Wildiers, H., Hurvitz, S.A., Guerrero-Zotano, A., Unni, N., Brufsky, A., Park, H., Waisman, J., Yang, E.S., Spanggaard, I., Reid, S., Burkard, M.E., Vinayak, S., Prat, A., Arnedos, M., Bidard, F.-C., Loi, S., Crown, J., Bhave, M., Piha-Paul, S.A., Suga, J.M., Chia, S., Saura, C., Garcia-Saenz, J.Á., Gambardella, V., de Miguel, M.J., Gal-Yam, E.N., Rapael, A., Stemmer, S.M., Ma, C., Hanker, A.B., Ye, D., Goldman, J.W., Bose, R., Peterson, L., Bell, J.S.K., Frazier, A., DiPrimeo, D., Wong, A., Arteaga, C.L., Solit, D.B.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article